tumor infiltrating lymphocyte
Showing 1 - 25 of >10,000
GT316,Solid Tumors,Adult Trial in Zhengzhou (GT316)
Recruiting
- GT316,Solid Tumors,Adult
- GT316
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Oct 16, 2023
Solid Tumor, Gynecological Tumors Trial in Shanghai (GT316)
Recruiting
- Solid Tumor
- Gynecological Tumors
- GT316
-
Shanghai, Shanghai, ChinaShanghai Tenth People's Hospital
Nov 17, 2023
Solid Tumor Trial in Shanghai (BEN101)
Not yet recruiting
- Solid Tumor
- BEN101
-
Shanghai, Shanghai, China
- +1 more
Apr 14, 2023
Solid Tumor Trial in Shanghai (GT201)
Recruiting
- Solid Tumor
- GT201
-
Shanghai, Shanghai, ChinaRenji Hospital Affiliated to Shanghai Jiaotong University School
Feb 1, 2023
Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects Trial in Shanghai (Tumor Infiltrating Lymphocyte)
Recruiting
- Advanced Melanoma
- +3 more
- Tumor Infiltrating Lymphocyte
-
Shanghai, ChinaShanghai Tenth People's Hospital
Dec 19, 2022
Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects Trial in Shanghai (Tumor Infiltrating Lymphocyte)
Recruiting
- Advanced Liver Cancers
- +4 more
- Tumor Infiltrating Lymphocyte
-
Shanghai, Shanghai, ChinaShanghai Tenth People's Hospital
Dec 19, 2022
Lymphocytes, Tumor-Infiltrating Trial in Saint Petersburg (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide,
Not yet recruiting
- Lymphocytes
- Tumor-Infiltrating
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
-
Saint Petersburg, Florida
- +1 more
Sep 15, 2023
Solid Tumor Trial in China (GT201)
Recruiting
- Solid Tumor
- GT201
-
Zhengzhou, Henan, China
- +4 more
Feb 6, 2023
Solid Tumor Trial in Hangzhou (GT201)
Recruiting
- Solid Tumor
- GT201
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang University
Jun 27, 2022
Advanced Melanoma Trial in Basel (Combination of Tumor-infiltrating lymphocyte transfer with ANV419)
Not yet recruiting
- Advanced Melanoma
- Combination of Tumor-infiltrating lymphocyte transfer with ANV419
-
Basel, SwitzerlandUniversity Hospital Basel
May 19, 2023
Metastatic or Recurrent Gynecological Tumors Trial in Shanghai (Autologous Tumor Infiltrating Lymphocyte Injection (GT202))
Recruiting
- Metastatic or Recurrent Gynecological Tumors
- Autologous Tumor Infiltrating Lymphocyte Injection (GT202)
-
Shanghai, Shanghai, ChinaThe Obstetrics and Gynecology Hospital of Fudan University
Feb 11, 2022
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma Trial in Tampa (TBio-4101, Cyclophosphamide, Fludarabine)
Recruiting
- Metastatic Melanoma
- +9 more
- TBio-4101
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
PDO/PDO-TIL/PDOTS for Drug Screen
Recruiting
- Liver Cancer
- Metastatic Liver Cancer
- Drug screen with PDO/PDO-TIL/PDOTS
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Jun 13, 2023
Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Tumor-infiltrating Lymphocytes (TIL)
- +5 more
-
Tampa, FloridaMoffitt Cancer Center
Dec 28, 2022
Glioblastoma Multiforme, Adult Trial in Shijiazhuang (Tumor Infiltrating Lymphocytes (TIL))
Recruiting
- Glioblastoma Multiforme, Adult
- Tumor Infiltrating Lymphocytes (TIL)
-
Shijiazhuang, Hebei, ChinaThe Second Hospital of HeBei Medical University
Apr 11, 2022
Epithelial Tumors, Malignant, Malignant Solid Tumor Trial in Barcelona (NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD)
Recruiting
- Epithelial Tumors, Malignant
- Malignant Solid Tumor
- NEXTGEN-TIL
- +2 more
-
Barcelona, SpainVall d'Hebron Institute of Oncology
Nov 25, 2021
Digestive System Malignant Solid Tumors Trial (ScTIL injection, ScTIL injection and B lymphocytes adjuvant)
Not yet recruiting
- Digestive System Malignant Solid Tumors
- ScTIL injection
- ScTIL injection and B lymphocytes adjuvant
- (no location specified)
Feb 7, 2023
Advanced Melanoma Trial in Basel (Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2)
Recruiting
- Advanced Melanoma
- Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
-
Basel, SwitzerlandDivision of Medical Oncology and Cancer Immunology, University H
Aug 3, 2021
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial in
Not yet recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Biospecimen Collection
- +8 more
-
Kansas City, KansasUniversity of Kansas Cancer Center
Nov 27, 2023
Metastatic Melanoma, Skin Cancer Trial run by the National Cancer Institute (NCI) (drug, biological, radiation)
Active, not recruiting
- Metastatic Melanoma
- Skin Cancer
- Aldesleukin
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Metastatic Melanoma Trial in New Haven (Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab)
Terminated
- Metastatic Melanoma
- Tumor Infiltrating Lymphocytes
- Nivolumab and Ipilimumab
-
New Haven, ConnecticutYale New Haven Hospital
Jul 20, 2022
Metastatic Melanoma Trial in Santa Monica (Tumor Infiltrating Lymphocytes (TIL))
Terminated
- Metastatic Melanoma
- Tumor Infiltrating Lymphocytes (TIL)
-
Santa Monica, CaliforniaJohn Wayne Cancer Institute
Aug 27, 2021
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)
Recruiting
- Bone Sarcoma
- +15 more
- Aldesleukin
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 3, 2022
Metastatic Melanoma Trial in Tampa (procedure, drug, other)
Active, not recruiting
- Metastatic Melanoma
- Surgery
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023